Description
Mechanism: Drug Affinity Complex (DAC)
The defining characteristic of this peptide is the addition of a reactive lysine linker at the C-terminus.
-
Albumin Binding: Upon introduction to the research subject, this reactive linker forms a covalent bond with endogenous serum albumin.
-
Enzymatic Shielding: This albumin conjugation acts as a protective shield, preventing degradation by the enzyme DPP-IV.
-
Extended Half-Life: While standard Mod GRF 1-29 has a half-life of roughly 30 minutes, the DAC complex extends the half-life to approximately 6–8 days in animal models.
-
Continuous Elevation: The result is a physiological “GH Bleed”—a continuous, steady-state elevation of Growth Hormone (GH) and Insulin-Like Growth Factor 1 (IGF-1) levels, rather than the natural pulsatile release seen with unmodified secretagogues.
⚠️ Critical Research Distinction
Please verify your research protocol before purchase.
-
THIS PRODUCT (CJC-1295 With DAC): Provides continuous, long-acting GH elevation for days.
-
CJC-1295 No DAC (Mod GRF): Provides short-acting, pulsatile spikes aimed at mimicking natural circadian rhythms.
This research peptide undergoes rigorous quality control and stability testing to ensure maximum integrity for scientific applications. Each batch is manufactured under strict laboratory conditions and verified through independent laboratory analysis.
⚠️ FOR RESEARCH PURPOSES ONLY
This product is strictly for in-vitro laboratory research, analysis, and development. It is not intended for human consumption, injection, or therapeutic use. CJC-1295 With DAC is not a drug, dietary supplement, or food. All statements regarding the physiological mechanisms of this peptide are based on preclinical animal and cell-culture studies and are provided for educational and informational purposes only.
Usage Context: Longitudinal Studies
The 5mg concentration is specifically optimized for longitudinal research studies where minimizing subject stress is a priority.
-
Infrequent Administration: Due to the multi-day half-life, this compound allows for once-weekly administration protocols.
-
Reduced Handling: This reduction in injection frequency is advantageous for reducing physiological stress markers in laboratory animals, potentially yielding cleaner data regarding long-term IGF-1 elevation.
Technical Specifications
-
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionic acid)-NH2
-
Conjugation: Drug Affinity Complex (Maleimidopropionic acid)
-
Purity: ≥99% (HPLC Verified)
-
Form: Lyophilized White Powder
-
Solubility: Water Soluble (Reconstitute with Bacteriostatic Water)
















